PL3151851T3 - Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu chorób, w których pośredniczy dopełniacz, u pacjentów z polimorfizmem c5 - Google Patents

Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu chorób, w których pośredniczy dopełniacz, u pacjentów z polimorfizmem c5

Info

Publication number
PL3151851T3
PL3151851T3 PL15728491T PL15728491T PL3151851T3 PL 3151851 T3 PL3151851 T3 PL 3151851T3 PL 15728491 T PL15728491 T PL 15728491T PL 15728491 T PL15728491 T PL 15728491T PL 3151851 T3 PL3151851 T3 PL 3151851T3
Authority
PL
Poland
Prior art keywords
complement
polymorphism
patients
treatment
mediated diseases
Prior art date
Application number
PL15728491T
Other languages
English (en)
Polish (pl)
Inventor
Wynne H Weston-Davies
Original Assignee
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals Sa filed Critical Volution Immuno Pharmaceuticals Sa
Publication of PL3151851T3 publication Critical patent/PL3151851T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL15728491T 2014-06-06 2015-06-08 Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu chorób, w których pośredniczy dopełniacz, u pacjentów z polimorfizmem c5 PL3151851T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism
EP15728491.0A EP3151851B1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Publications (1)

Publication Number Publication Date
PL3151851T3 true PL3151851T3 (pl) 2022-04-04

Family

ID=51266841

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15728491T PL3151851T3 (pl) 2014-06-06 2015-06-08 Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu chorób, w których pośredniczy dopełniacz, u pacjentów z polimorfizmem c5
PL15807907T PL3302519T3 (pl) 2014-06-06 2015-12-09 Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu ostrej choroby przeszczep przeciwko gospodarzowi

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15807907T PL3302519T3 (pl) 2014-06-06 2015-12-09 Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu ostrej choroby przeszczep przeciwko gospodarzowi

Country Status (16)

Country Link
US (3) US11052129B2 (enExample)
EP (1) EP3151851B1 (enExample)
JP (2) JP7045133B2 (enExample)
KR (1) KR102439717B1 (enExample)
CN (1) CN106659767B (enExample)
AU (1) AU2015270396B2 (enExample)
BR (1) BR112016028446A2 (enExample)
CA (1) CA2951175A1 (enExample)
DK (2) DK3151851T3 (enExample)
ES (2) ES2906630T3 (enExample)
GB (1) GB201410116D0 (enExample)
IL (1) IL249237B (enExample)
MX (1) MX382757B (enExample)
PL (2) PL3151851T3 (enExample)
RU (1) RU2700932C2 (enExample)
WO (1) WO2015185760A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2019521105A (ja) * 2016-06-07 2019-07-25 ノバルティス アーゲー 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体
SE540754C2 (en) * 2016-11-30 2018-10-30 Ikea Supply Ag Molding of fiber blanks into three-dimensional fiber block
ES2945433T3 (es) * 2017-04-21 2023-07-03 Volution Immuno Pharmaceuticals Sa Coversina para el tratamiento de enfermedades ampollares autoinmunes
JP7153669B2 (ja) * 2017-04-21 2022-10-14 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 瘢痕性眼炎症障害の治療のためのコバーシン
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
EP3849588A1 (en) * 2018-09-10 2021-07-21 Volution Immuno Pharmaceuticals SA Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
DE602004020334D1 (de) 2003-06-02 2009-05-14 Varleigh Ltd Komplementinhibitoren aus zecken
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
WO2008029169A2 (en) 2006-09-08 2008-03-13 Varleigh Limited Method of treating respiratory disorders
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
NZ601018A (en) * 2010-01-08 2013-09-27 Varleigh Immuno Pharmaceuticals Ltd Ev576 for use in the treatment of viral infections of the respiratory tract
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
ES2945433T3 (es) 2017-04-21 2023-07-03 Volution Immuno Pharmaceuticals Sa Coversina para el tratamiento de enfermedades ampollares autoinmunes

Also Published As

Publication number Publication date
JP6767396B2 (ja) 2020-10-14
KR102439717B1 (ko) 2022-09-02
WO2015185760A1 (en) 2015-12-10
IL249237B (en) 2020-09-30
NZ727053A (en) 2023-10-27
DK3151851T3 (da) 2022-02-28
US11052129B2 (en) 2021-07-06
PL3302519T3 (pl) 2022-04-25
DK3302519T3 (da) 2022-02-28
JP7045133B2 (ja) 2022-03-31
ES2906632T3 (es) 2022-04-19
RU2016151179A (ru) 2018-07-16
KR20170016893A (ko) 2017-02-14
CN106659767B (zh) 2022-08-30
MX382757B (es) 2025-03-13
GB201410116D0 (en) 2014-07-23
AU2015270396B2 (en) 2020-07-16
CN106659767A (zh) 2017-05-10
JP2017518316A (ja) 2017-07-06
US20180193417A1 (en) 2018-07-12
JP2018516944A (ja) 2018-06-28
US20210283221A1 (en) 2021-09-16
RU2016151179A3 (enExample) 2019-01-22
AU2015270396A1 (en) 2016-12-15
MX2016016139A (es) 2017-07-28
IL249237A0 (en) 2017-02-28
RU2700932C2 (ru) 2019-09-24
US20170196936A1 (en) 2017-07-13
CA2951175A1 (en) 2015-12-10
ES2906630T3 (es) 2022-04-19
EP3151851B1 (en) 2021-12-01
EP3151851A1 (en) 2017-04-12
BR112016028446A2 (pt) 2017-10-24

Similar Documents

Publication Publication Date Title
IL249237B (en) Ornithodorus Mobate complement inhibitor for use in the treatment of complement-induced diseases in patients with the c5 polymorphism
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
GB201515986D0 (en) Use of cannabinoids in the treatment of mental disorders
SG11201509012QA (en) Sobetirome in the treatment of myelination diseases
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
EP3218481A4 (en) Biomarkers useful in the treatment of subjects having diseases of the eye
IL246855A0 (en) Materials for use in the treatment of retinitis
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
EP3096775A4 (en) Socs mimetics for the treatment of diseases
GB201617820D0 (en) Dental treatment
HUE046209T2 (hu) Kompozíció porckoronggal összefüggõ fájdalom kezelésében történõ alkalmazásra
SI3548006T1 (sl) Sestava za uporabo pri zdravljenju črevesnih sprememb
IL252493B (en) Compounds for use in the prevention or treatment of cancer
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
EP3184055A4 (en) Medical treatment instrument
GB201500361D0 (en) Polyaryletherketone prosthodontics device in the form of an inlay or onlay
GB201513543D0 (en) Compositions for use in the treatment of diabetes
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
HK1242990A1 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
ZA201404780B (en) Composition for use in treatment of diabetes
ZA201408464B (en) Composition for the use in treatment of asthma